Coagulation disorders in liver diseases

HAEMA

Volumn 9, Issue 1, 2006, Pages 29-42

  Soultati, Aspasia ^a   Dourakis, Spyros P ^a,b  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

Coagulation disorders; Cryoglobulinemia; Ehlers Danlos syndrome; Henoch Schonlein purpura; Hereditary hemorrhagic telangiectasia; Kasabach Merritt syndrome; Thrombasthenia; Thrombotic thrombocytopenic purpura; Uremic hemolytic syndrome

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN III; APROTININ; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING INHIBITOR; CARDIOLIPIN ANTIBODY; DESMOPRESSIN; FLUOROURACIL; FRESH FROZEN PLASMA; GEMCITABINE; HEPARIN; IMMUNOSUPPRESSIVE AGENT; LUPUS ANTICOAGULANT; PROTHROMBIN COMPLEX; RECOMBINANT PROTEIN; STEROID; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; VITAMIN K GROUP;

AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE HEPATITIS; BLEEDING; BLEEDING TENDENCY; BLOOD CLOTTING DISORDER; CELL ACTIVATION; CHRONIC LIVER DISEASE; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DYSFIBRINOGENEMIA; ENDOTHELIUM CELL; FATALITY; FIBRINOLYSIS; HEMOLYTIC UREMIC SYNDROME; HEMOSTASIS; HEPATIC ENCEPHALOPATHY; HUMAN; JAUNDICE; LIVER CELL; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER TUMOR; METABOLIC DISORDER; PARTIAL THROMBOPLASTIN TIME; PLASMAPHERESIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PROTHROMBIN TIME; REVIEW; SPLENECTOMY; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VIRUS HEPATITIS; VITAMIN K DEFICIENCY;

EID: 33646455004     PISSN: 11082682     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Goldman L, Bennett JC. In Cecil textbook of medicine: Hematologic diseases. Approach to the patient with bleeding and thrombosis, 21st Edition. Saunders pp. 991-996.
2. Heneghan MA, Lara L. Fulminant hepatic failure. Semin Gastrointest Dis 2003; 14: 87-100.
3. Pereira SP, Langley PG, Williams R. The management of abnormalities of hemostasis in acute liver failure. Semin Liver Dis 1996; 16: 403-414.
4. Gimson AE, Braude S, Mellon PJ et al. Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet 1982; 2: 681-683.
5. Gimson AE, O'Grady J, Ede RJ et al. Late onset hepatic failure: clinical, serological and histological features. Hepatology 1986; 6: 288-294.
6. Weston MJ, Langley PG, Rubin MH, Hanid MA, Mellon P, Williams R. Platelet function in fulminant hepatic failure and effect of charcoal haemoperfusion. Gut 1977; 18: 897-902.
7. Rake MO, Flute PT, Panell G, Williams R. Inravascular coagulation in acute hepatic necrosis. Lancet 1970; 2: 533-537.
8. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis 2002; 22: 83-96.
9. Boks AL, Brommer EJP, Schalm SW, Van Vliet HH. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 1986; 6: 79-86.
10. Gizzard BG, Clark R, Flute PT, Williams R. Factor VIII levels during the course of acute hepatitis in hemophiliacs. J Clin Pathol 1975; 28: 972-974.
11. Langley PG, Hughes RD, Williams R. Increased factor VIII complex in fulminant hepatic failure. Thromb Haem 1985; 54: 693-696.
12. Gabriel DA. The use of antithrombin III in the treatment of disseminated intravascular coagulation. Sem Haematol 1994; 31: 60-64.
13. Langley PG, Williams R. Physiological inhibitors of coagulation in fulminant hepatic failure. Blood Coag Fibrinol 1992; 3: 243-247.
14. Langley PG, Forbes A, Hughes RD, Williams R. Thrombin antithrombin III complex in fulminant hepatic failure: evidence for disseminated intravascular coagulation and relationship to outcome. Eur J Clin Invest 1990; 20: 627-631.
15. Hughes RD, Lane DA, Ireland H et al. Fibrinogen derivatives and platelet activation products in acute and chronic liver disease. Clin Sc 1985; 68: 701-707.
16. Gallus AS, Lucas CR, Hirsh J. Coagulation studies in patients with acute infectious hepatitis. Br J Haematol 1972; 22: 761-771.
17. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with non-alcoholic chronic liver disease. Am J Gastroenterol 2000; 95: 2936-2939.
18. Lechner K, Niessner H, Thaler E. Coagulation abnormalities in liver disease. Semin Thromb Hemost 1977; 4: 40-56.
19. Rubin MH, Weston MJ, Langley MH, et al. Platelet function in chronic liver disease: relationship to disease severity. Dig Dis Sci 1979; 24: 197-202.
20. Glassman AB. Platelet abnormalities in hepatobiliary diseases. Ann Clin Lab Sci 1990; 20: 119-122.
21. Sanchez Roig MJ, Rivera J, Moraleda JM, Martinez I, Vicente V. An acquired Bernard Soulier like platelet defect in a patient with liver cirrhosis. Eur J Haematol 1994; 52: 240-242.
22. Quintarelli C, Ferro D, Valesini G, Basili S, Tassone G, Violi F. Prevalence of lupus anticoagulant in patients with cirrhosis: relationship with beta-2-glycoprotein I plasma levels. J Hepatol 1994; 21: 1086-1091.
23. Denninger MH, Chait Y, Casadevall N et al. Cause of portal and hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31: 587-591.
24. Green G, Poller L, Thomsen JM et al. Factor VII as a marker of hepatocellular synthetic function in liver disease. J Clin Pathol 1976; 29: 971-997.
25. Paramo JA, Rocha E. Hemostasis in advanced liver disease. Semin Thromb Hemost 1993; 19: 184-190.
26. Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost 2004; 91: 267-275.
27. Rodriguez-Inigo E, Bartolome J, Quiroga JA et al. Expression of factor VII in the liver of patients with liver disease: correlations with the disease severity and impairment in the hemostasis. Blood Coagul Fibrinolysis 2001; 12: 193-199.
28. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis 2002; 22: 83-96.
29. Iber FI, Shamszad M, Miller PA et al. Vitamin K deficiency in chronic alcoholic males. Alcohol Clin Exp Res 1986; 10: 679-681.
30. Drin FG, Thomson JM, Dymock IW et al. Abnormal fibrin polymerization in liver disease. Br J Haematol 1976; 34: 427-437.
31. Barr RD, Allardyce M, Brunt PW, McPhie JL. Dysfibrinogenemia and liver cell growth, J Clin Pathol 1978; 31: 89-92.
32. Francis RB, Feinstein DI. Clinical significance of accelerated fibrinolysis in liver disease. Haemostasis 1984; 14: 460-465.
33. Hu KQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001; 96: 1581-1586.
34. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-592.
35. Ben- Ari Z, Osman E, Hutton RA et al. Disseminated intravascular coagulation in liver cirrhosis:fact or fiction? Am J Gastroenterol 1999; 94: 2977-2982.
36. Bajaj JS, Bhattacharjee J, Sarin SK. Coagulation profile and platelet function in patients with extrahepatic portal vein obstruction and non-cirrhotic portal fibrosis. J Gastroenterol Hepatol 2001; 16: 641-646.
37. Pihusch R, Rank A, Gohring P, Pihusch M, Hiller E, Beuers U. Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. J Hepatol 2002; 37: 548-555.
38. Samuel H, Nardi M, Karpatkin M, Hart D, Belmont M, Karpatkin S. Differentiation of autoimmune thrombocytopeia from thrombocytopenia associated with immune complex disease:systemic lupus erythematosus, hepatitis-cirrhosis, and HIV-1 infection by platelet and seru immunological measurements. Br J Haematol 1999; 105: 1086-1091.
39. Leleu X, Chevalier J, Mahieu M, Rose C. Primary biliary cirrhosis revealed by autoimmune thrombopenic purpura. Presse Med 1998; 27: 1897-1898.
40. Yoshiba EM, Mandl LA, Erb SR, Buckley AB, Scudamore CH, Busk NA. Idiopathic thrombocytopenic purpura in a liver transplant receiver with previous primary biliary cirrhosis. J Clin Gastroenterol 1997; 24: 274-275.
41. Fickert P, Trainer M, Sill H, Hinterleitner TA, Stauber RE. Successful steroid treatment of idiopathic thrombocytopenic purpura after orthotopic liver transplantation for primary biliary cirrhosis. Am J Gastroenterol 1998; 93: 1985-1986.
42. Mizukami Y, Ohhira M, Matsumoto A et al. Primary biliary cirrhosis associated with idiopathic thrombocytopenic purpura. J Gastroenterol 1996; 31: 284-288.
43. Wallerstedt S, Westin J, Hansson G. Primary biliary cirrhosis presenting as idiopathic thrombocytopenic purpura with deterioration after splenectomy. J Intern Med 1989; 225: 279-283.
44. Arakawa Y, Amaki S, Miyakawa H et al. PBC-AIH overlap syndrome with concomitant ITP and Hashimoto's disease with positivity for anti-centromere antibodies. J Gastroenterol 2004; 39: 490-495.
45. Zugmaier G, Jager R, Neubauer A, Mennel HD, Knabbe C, Dienes HP. Fatal bleeding complications caused by Evans syndrome (autoimmune thrombocytopenia and hemolytic anemia) and type II autoimmune hepatitis in a 56-year-old patient. Med Klin (Munich) 2002; 97: 88-90.
46. Sakai M, Egawa N, Sakamaki H et al. Primary sclerosing cholangitis complicated with idiopathic thrombocytopenic purpura. Intern Med 2001; 40: 1209-1214.
47. Beales IL. An acquired-pseudo Bernard Soulier syndrome occurring with autoimmune chronic active hepatitis and anti-cardiolipin antibodies. Postgrad Med J 1994; 70: 305-308.
48. Sherlock S. Nutritional complications of biliary cirrhosis. Chronic cholestasis Am J Clin Nutr 1970; 23: 640-644.
49. Segal H, Cottam S, Potter D et al. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatology 1997; 25: 683-688.
50. Nagaratnam N, Ambepitiya G, Rajaratnam RG, Jayasinghe NS. Lupoid hepatitis, Rendu-Osler-Weber syndrome, clubbing, cyanosis and hypertrophic asteoarthropathy. J Med 1975; 6: 291-301.
51. Hays SB, Camisa C. Rendu-Osler-Weber-like telangiectasia associated with primary biliary cirrhosis. Cutis 1985; 35: 152-153.
52. Panzer S, Seel E. Is there an increased frequenc of autoimmune thrombocytopenia in hepatitis C infection? A review. Wien Med Wochenschr 2003; 153: 417-420.
53. Doi T, Homma H, Mezawa S et al. Mechanisms for increment of platelet associated IgG and platelet surface IgG and their implications in immune thrombocytopenia associated with chronic viral liver disease. Hepatol Res 2002; 24: 23.
54. Pockros PJ, Duchini A, McMillan R et al. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2002; 97: 2040-2045.
55. Kusaba N, Yoshida H, Ohkubo F, Shimokawa Y, Sata M. Autoimmune thrombocytopenia and erythroid hypoplasia associated with hepatitis A. Rinsho Ketsueki 2000; 41: 739-744.
56. Fusegawa H, Shiraishi K, Ogasawara F et al. Platelet activation in patients with chronic hepatitis C. Tokai J Exp Clin Med 2002; 27: 101-106.
57. Poujol-Robert A, Rosmordue O, Serfaty L, Coulet F, Poupon R. Genetic and acquired thrombotic factors in chronic hepatitis C. Am J Gastroenterol 2004; 99: 527-531.
58. Barbirotto RM, Fagundes-Neto U, Wehba J, Patricio FR, Michalany NS. Hereditary hemorrhagic telangiectasia associated to chronic hepatitis. Arq Gastroenterol 1980; 17: 109-113.
59. Madison DL, Allen E, Deodhar A, Morrison L. Henoch Schonlein purpura: a possible complication of hepatitis C related liver cirrhosis. Ann Rheum Dis 2002; 61: 281-282.
60. Ferri C, Sebastiani M, Giuggioli D et al. Mixed cryoglobulinemia: demographic, clinical and serological features and survival in 231 patients. Semin Arthritis Rheum 2004; 33: 355-374.
61. Takatsuki M, Uemoto S, Kurokawa T, Koshiba T, Inomata Y, Takana K. Idiopathic thrombocytopenic purpura after a living-related liver transplantation. Transplantation 1999; 67: 479-481.
62. Aghai E, Quitt M, Lurie M et al. Primary hepatic lymphoma presenting as symptomatic immune thrombocytopenic purpura. Cancer 1987; 60: 2308-2311.
63. Pinchas-Hamiel O, Mandel M, Engelberg S, Passwell JH. Immune hemolytic anemia, thrombocytopenia and liver disease in a patient with DiGeorge syndrome. Isr J Med Sci 1994; 30: 530-532.
64. Sagawa M, Takao M, Nogawa S et al. Wilson's disease associated with olfactory paranoid syndrome and idiopathic thrombocytopenic purpura. No To Shinkei. 2003; 55: 899-902.
65. Funabiki Y, Satoh H, Yoshinami N et al. Liver abscess accompanied by TTP and Liddle's syndrome. Nippon Naika Gakkai Zasshi 2000; 89: 1427-1429.
66. Kellick S, Jeffery S, Tter M, Rist C, Bevan D. Thrombotic thrombocytopenic purpura in a patient with genetic haemochromatosis, liver cirrhosis and an iron free focus. Br J Haematol 1997; 99: 839-841.
67. Szotkowski T, Frysak Z, Papajik T et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) leading to the diagnosis of Wilson's disease. Vnitr Lek 2002; 48: 353-356.
68. Nally JV, Metz EN. Acute thrombotic thrombocytopenic purpura. Another cause of haemolytic anemia and thrombocytopenia in cirrhosis. Arch Intern Med 1979; 139: 711-712.
69. Yoshida K, Arakawa M, Ishida S, Sasaki Y. A case of hemolytic uremic syndrome associated with emphysematous cholecystitis and a liver abscess. Tohoku J Exp Med 1998; 185: 147-155.
70. Seo DW, Lee YS, Chae JG et al. Hepatocellular carcinoma associated haemolytic uremic syndrome unrelated to chemotherapy. J Korean Med Sci 1994; 9: 254-258.
71. Eckel F, Lersch C, Erdmann J, Schmidt B, Schulte-Frohlinde E. A 42 year old patient with the hemolytic uremic syndrome under gemcitabine therapy for an adenocarcinoma of the liver. The hemolytic-uremic syndrome and gemcitabine. Z Gastroenterol 2000; 38: 593-596.
72. Rerolle JP, Akposso K, Lerolle N et al. Tacrolimus-induced hemolytic uremic syndrome and end-stage renal failure after liver transplantation. Clin Transplant 2000; 14: 262-265.
73. Vogel T, Lammers B, von Herbay A, et al. Kasabach Merritt syndrome in giant hemangioma of the liver. Chirurg 2002; 73: 729-732.
74. Imanishi H, Kawata M, Yanagihara M et al. Epithelioid hemangioendothelioma of the liver associated with thrombocytopenia and coagulopathy. Hepatogastroenterology 2002; 49: 1673-1675.
75. Mewes T, Moldenhauer H, Pfeifer J, Papenberg J. The Kasabach Merritt syndrome: severe bleeding disorder caused by celiac arteriography-reversal by heparin treatment. Am J Gastroenterol 1989; 84: 965-971.
76. el Dessouki M, Azmy AF, Raine PA, Young DG. Kasabach Merritt syndrome. J Pediatr Surg 1988; 23: 109-111.
77. Denninger MH. Liver diseases and hemostasis. Pathol Biol (Paris) 1999; 47: 1006-1015.
78. Bacon RB, Di Bisceglie AM. Complications of cirrhosis: Hemostatic profile in: Liver disease. Diagnosis and management. Textbook. Editors Churchill Livingston, 2000, pp. 261-268.
79. Munoz SJ, Ballas SK, Mritz MJ et al. Perioperative management of fulminant and subfulminant hepatic failure with therapeutic plasmapheresis. Transplant Proc 1989; 21: 3535-3536.
80. Kondrup J, Almdal T, Vilstrup H, Tygstrup N. High volume plasma exchange in fulminant hepatic failure. Int J Artif Organs 1992; 15: 669-676.
81. Gazzard BG, Henderson JM, Williams R. Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy. Gut 1975; 16: 617-620.
82. Langley PG, Hughes RD, Forbes A, Keays R, Williams R. Controlled trial of antithrombin III supplementation in fulminant hepatic failure. J Hepatol 1993; 17: 326-331.
83. Macik BG, Lindley CN, Lusher J et al. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII. Results of a phase I study. Blood Coagul Fibrinolysis 1993; 4: 521-527.
84. Shami VM, Caldwell SH, Hespenheide EE, Arseneau KO, Bickston SJ, Macik BG. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003; 9: 138-143.
85. Bernstein DE, Jeffers L, Erhardtsen E et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients. A preliminary study. Gastroenterology 1997; 113: 1930-1937.